PAF
MCID: PRT058
MIFTS: 52

Pure Autonomic Failure (PAF) malady

Categories: Rare diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Pure Autonomic Failure

Aliases & Descriptions for Pure Autonomic Failure:

Name: Pure Autonomic Failure 50 56 52 69
Idiopathic Orthostatic Hypotension 50 56 69
Bradbury-Eggleston Syndrome 50 51 56
Orthostatic Hypotension 50 51 29
Bradbury Eggleston Syndrome 50
Pure Idiopatic Dysautonomia 56
Hypotension Orthostatic 52
Pure Dysautonomia 56
Paf 56

Characteristics:

Orphanet epidemiological data:

56
pure autonomic failure
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult; Age of death: elderly;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Orphanet 56 ORPHA441
MESH via Orphanet 43 D054970 C544351
UMLS via Orphanet 70 C0393911 C2931939
ICD10 via Orphanet 34 G90.3
ICD10 33 I95.1

Summaries for Pure Autonomic Failure

NINDS : 51 Orthostatic hypotension is a sudden fall in blood pressure that occurs when a person assumes a standing position. It is due to a lesion of the baroreflex loop, which senses a change in blood pressure and adjusts heart rate and activates sympathetic nerve system fibers to cause the blood vessels to narrow and correct blood pressure. It may also be caused by hypovolemia (a decreased amount of blood in the body), resulting from the excessive use of diuretics, vasodilators, or other types of drugs, dehydration, or prolonged bed rest. The disorder may be associated with Addison's disease, diabetes, and certain neurological disorders including Multiple System Atrophy with Orthostatic Hypotension (formerly known as Shy-Drager syndrome), autonomic system neuropathies, and other dysautonomias. Symptoms, which generally occur after sudden standing, include dizziness, lightheadedness, blurred vision, and syncope (temporary loss of consciousness).

MalaCards based summary : Pure Autonomic Failure, also known as idiopathic orthostatic hypotension, is related to multiple system atrophy and myocardial infarction. An important gene associated with Pure Autonomic Failure is DBH (Dopamine Beta-Hydroxylase), and among its related pathways/superpathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Circadian entrainment. The drugs Droxidopa and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include heart, spinal cord and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

NIH Rare Diseases : 50 pure autonomic failure is characterized by generalized autonomic failure without central nervous system (brain or spinal cord) involvement. the autonomic nervous system is the part of our bodies that controls involuntary actions, such as the widening or narrowing of our blood vessels. failure of this system can cause a variety of symptoms. the most common symptom of pure autonomic failure is orthostatic hypotension. other symptoms may include decreased sweating, heat intolerance, inability to empty the bladder, erectile dysfunction, incontinence or constipation, and pupil changes. the cause of this condition is usually unknown. last updated: 4/9/2015

Wikipedia : 71 Pure autonomic failure (PAF), also known as Bradbury-Eggleston syndrome or idiopathic orthostatic... more...

Related Diseases for Pure Autonomic Failure

Diseases related to Pure Autonomic Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
id Related Disease Score Top Affiliating Genes
1 multiple system atrophy 32.4 MAOB SNCA
2 myocardial infarction 28.7 ACE GNB3 NPPA PDE5A REN
3 autonomic dysfunction 11.3
4 primary orthostatic hypotension 11.1
5 platelet-activating factor acetylhydrolase deficiency 11.0
6 dysautonomia 10.9
7 dysautonomia, familial 10.9
8 orthostatic intolerance 10.6
9 hypotrichosis simplex 10.3 ACE REN
10 hyperinsulinemic hypoglycemia, familial, 3 10.3 ACE REN
11 dystonia-1, torsion 10.3 DBH DDC
12 carbohydrate metabolic disorder 10.3 ACE REN
13 hypothyroidism, congenital nongoitrous, 5 10.3 ACE REN
14 cerebral atrophy 10.3 DBH SNCA
15 listeriosis 10.3 ACE REN
16 familial spastic paralysis 10.2 DBH SNCA
17 inferolateral myocardial infarct 10.2 ACE NPPA
18 cavernous hemangioma 10.2 DDC SNCA TH
19 dientamoebiasis 10.2 ACE EPO REN
20 kartagener syndrome 10.2 ACE PDE5A
21 hypogonadism mitral valve prolapse mental retardation 10.2 ACE NPPA REN
22 iris disease 10.2 ACE NPPA REN
23 eastern equine encephalitis 10.2 ACE NPPA REN
24 myopia 10.2 ACE NPPA REN
25 lymphadenitis 10.2 ACE NPPA REN
26 clear cell adenocarcinoma 10.2 ACE NPPA REN
27 pyelonephritis 10.2 ACE NPPA REN
28 ceroid lipofuscinosis, neuronal, kufs type, adult onset 10.2 ACE NPPA REN
29 gastroesophageal reflux 10.1
30 calcinosis 10.1 ACE EPO REN
31 congenital nystagmus 10.1 ACE REN
32 hypopigmentation of eyelid 10.1 PDE5A SNCA
33 cytomegalic congenital adrenal hypoplasia 10.1 DBH MAOA TH
34 meier-gorlin syndrome 5 10.1 ACHE SNCA TH
35 petrositis 10.1 ACE DBH EPO REN
36 shaken baby syndrome 10.1 DBH DDC NPPA REN
37 rapidly progressive glomerulonephritis 10.1 ACE NPPA PDE5A
38 endotheliitis 10.1
39 nephrogenic adenoma of the urethra 10.1 DBH MAOB SNCA
40 body dysmorphic disorder 10.1 ACE REN TTR
41 hypoparathyroidism-intellectual disability-dysmorphism syndrome 10.1 ACHE TH
42 pheochromocytoma 10.1 DBH DDC NPPA TH
43 cervix small cell carcinoma 10.1 ACE ACHE REN
44 lipoprotein lipase deficiency 10.1 PDE5A SNCA
45 critical limb ischemia 10.0 ACE EPO NPPA REN
46 chronic myocardial ischemia 10.0 ACE EPO REN TTR
47 movement disease 10.0 DDC TH
48 lung giant cell carcinoma 10.0 ACE EPO NPPA REN
49 autism 19 10.0 DBH MAOB SNCA TH
50 conjunctival pigmentation 10.0 MAOA MAOB

Graphical network of the top 20 diseases related to Pure Autonomic Failure:



Diseases related to Pure Autonomic Failure

Symptoms & Phenotypes for Pure Autonomic Failure

MGI Mouse Phenotypes related to Pure Autonomic Failure:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 ACE ACHE DBH DDC MAOA MAOB
2 homeostasis/metabolism MP:0005376 10.07 NEDD4L NPPA REN SNCA TH TTR
3 cardiovascular system MP:0005385 10.02 ACE DBH DDC EPO MAOA NEDD4L
4 nervous system MP:0003631 9.85 ACHE DBH DDC GNB3 MAOA MAOB
5 renal/urinary system MP:0005367 9.5 MAOB NEDD4L NPPA REN SNCA ACE
6 vision/eye MP:0005391 9.17 TTR ACHE DBH DDC GNB3 NEDD4L

Drugs & Therapeutics for Pure Autonomic Failure

Drugs for Pure Autonomic Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 342)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23651-95-8 443940
2
Norepinephrine Approved Phase 4,Phase 1,Phase 2 51-41-2 439260
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
4
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1 59-92-7 6047
5
Acetaminophen Approved Phase 4 103-90-2 1983
6
Losartan Approved Phase 4,Phase 1 114798-26-4 3961
7
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 1 58-93-5 3639
8
Amlodipine Approved Phase 4 88150-42-9 2162
9
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
10
Metoprolol Approved, Investigational Phase 4,Phase 1 37350-58-6, 51384-51-1 4171
11
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 1 525-66-6 4946
12
Methylphenidate Approved, Investigational Phase 4,Phase 1 113-45-1 4158
13
Midodrine Approved Phase 4,Phase 3,Phase 2,Phase 1 133163-28-7, 42794-76-3 4195
14
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
15
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
16
Mirabegron Approved Phase 4,Phase 2 223673-61-8
17 Pyridostigmine Bromide Phase 4,Phase 2,Phase 1 101-26-8
18 diuretics Phase 4,Phase 3,Phase 2,Phase 1
19
Serotonin Phase 4,Phase 2,Phase 1,Early Phase 1 50-67-9 5202
20 Cholinergic Agents Phase 4,Phase 2,Phase 1
21 Cholinesterase Inhibitors Phase 4,Phase 2,Phase 1
22 Natriuretic Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
26 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 1
27 Anticonvulsants Phase 4,Phase 2,Phase 1
28 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Bromides Phase 4,Phase 2,Phase 1
32 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
33
Angiotensin II Phase 4,Phase 3,Phase 1,Early Phase 1 68521-88-0, 11128-99-7 65143 172198
34 Analgesics Phase 4,Phase 1,Phase 2
35 calcium channel blockers Phase 4,Phase 2,Phase 1
36 Adrenergic Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
37 Narcotics Phase 4,Phase 2
38 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
39 Adrenergic Agonists Phase 4,Phase 3,Phase 1,Phase 2
40 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 1,Phase 2
42 Sodium Chloride Symporter Inhibitors Phase 4,Phase 1
43 Adrenergic beta-1 Receptor Antagonists Phase 4,Phase 1
44 Adrenergic beta-Agonists Phase 4,Phase 2,Phase 1
45 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 1
46 Sympatholytics Phase 4,Phase 3,Phase 1,Phase 2
47 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
48 Analgesics, Opioid Phase 4
49 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 215)
id Name Status NCT ID Phase
1 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4
2 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4
3 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4
4 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01515865 Phase 4
5 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study Completed NCT02308124 Phase 4
6 Comparision of Blood Pressure Variability Between Amlodipine and Losartan Completed NCT01964079 Phase 4
7 Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease Completed NCT00914134 Phase 4
8 AMISH : Aprovel for Management of Isolated Systolic Hypertension Completed NCT00264212 Phase 4
9 Adjuvant Analgesic Effects of Low Dose Tramadol/Acetaminophen Combination After Open Gynaecological Surgery Completed NCT00942565 Phase 4
10 Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc Completed NCT00853840 Phase 4
11 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4
12 A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients Completed NCT00406848 Phase 4
13 Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance Completed NCT00060866 Phase 4
14 Dawn Simulation and Postural Hypotension Recruiting NCT02632318 Phase 4
15 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Recruiting NCT02586623 Phase 4
16 Mirabegron in Parkinson Disease and Impaired Cognition Recruiting NCT02536976 Phase 4
17 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4
18 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4
19 The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease. Terminated NCT01244269 Phase 4
20 A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients Unknown status NCT01314625 Phase 3
21 Post-Exercise Hypotension in Elderly Hypertensive Men Unknown status NCT02415582 Phase 3
22 Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty Completed NCT01707953 Phase 3
23 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3
24 A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease Completed NCT01176240 Phase 3
25 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3
26 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304) Completed NCT01132326 Phase 3
27 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3
28 Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy Completed NCT01522235 Phase 2, Phase 3
29 Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients Completed NCT02445898 Phase 2, Phase 3
30 Exhaled Levels of Nitric Oxide Completed NCT00753948 Phase 2, Phase 3
31 Efficacy and Safety of Primovist in Chinese Patients Completed NCT00526188 Phase 3
32 Prevention of Low Blood Pressure in Persons With Tetraplegia Completed NCT00237770 Phase 2, Phase 3
33 LEPU Renal Denervation System for Resistant Hypertension Completed NCT02536326 Phase 3
34 A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication Completed NCT01195662 Phase 3
35 A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients. Completed NCT00145171 Phase 3
36 A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone Completed NCT00528879 Phase 3
37 Stop Vasodepressor Drugs in Reflex Syncope Completed NCT02137278 Phase 3
38 Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA Recruiting NCT02071459 Phase 2, Phase 3
39 An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease Recruiting NCT02542696 Phase 3
40 Efficacy of Transcatheter Ablation Using Anatomic Approach of Ganglionated Plexi Located in the Right Atrium to Prevent Neuromediated Cardioinhibitory Syncope Recruiting NCT01814228 Phase 3
41 Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3
42 Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury Recruiting NCT02307565 Phase 3
43 Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip Recruiting NCT02683239 Phase 3
44 Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE) Recruiting NCT02597361 Phase 3
45 Treatment of Orthostatic Hypotension Enrolling by invitation NCT00581477 Phase 3
46 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome Not yet recruiting NCT03182725 Phase 3
47 Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients Terminated NCT01612078 Phase 3
48 A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy Terminated NCT01927055 Phase 3
49 Tamsulosin for Urinary Retention in Hospitalized Older Women Terminated NCT01747993 Phase 3
50 Effects of Pulsatile Intravenous Insulin Therapy on Metabolic Integrity in Patients With Diabetes Mellitus Terminated NCT00539409 Phase 2, Phase 3

Search NIH Clinical Center for Pure Autonomic Failure

Genetic Tests for Pure Autonomic Failure

Genetic tests related to Pure Autonomic Failure:

id Genetic test Affiliating Genes
1 Orthostatic Hypotension 29

Anatomical Context for Pure Autonomic Failure

MalaCards organs/tissues related to Pure Autonomic Failure:

39
Heart, Spinal Cord, Brain, Skin, Cingulate Cortex, Colon, Cortex

Publications for Pure Autonomic Failure

Articles related to Pure Autonomic Failure:

(show top 50) (show all 79)
id Title Authors Year
1
Skin nerve misfolded I+-synuclein in pure autonomic failure and Parkinson disease. ( 26606657 )
2016
2
Pure Autonomic Failure. ( 27338613 )
2016
3
A case series of REM sleep behavior disorder in pure autonomic failure. ( 27757562 )
2016
4
Successful long-term ambulatory norepinephrine infusions in a patient with pure autonomic failure. ( 26138858 )
2015
5
Skin sympathetic fiber I+-synuclein deposits: A potential biomarker for pure autonomic failure. ( 24379100 )
2014
6
Alpha-synuclein accumulation in a patient with Auerbach's plexus of pure autonomic failure. ( 25274243 )
2014
7
Antemortem detection of colonic I+-synuclein pathology in a patient with pure autonomic failure. ( 25319021 )
2014
8
Pure autonomic failure with cold induced sweating. ( 23511064 )
2013
9
Skin sympathetic fiber I+-synuclein deposits: a potential biomarker for pure autonomic failure. ( 23390175 )
2013
10
Incidence of cerebrovascular lesions in pure autonomic failure. ( 23706609 )
2013
11
Pure autonomic failure. ( 24095130 )
2013
12
I+-Synuclein in the skin nerve of pure autonomic failure. ( 22186004 )
2011
13
alpha-synuclein accumulation in skin nerve fibers revealed by skin biopsy in pure autonomic failure. ( 20157164 )
2010
14
Pure autonomic failure: a restricted Lewy body synucleinopathy or early Parkinson disease? ( 20157156 )
2010
15
Autonomic innervation in multiple system atrophy and pure autonomic failure. ( 20660924 )
2010
16
Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases. ( 19201246 )
2009
17
Differences in skin sympathetic involvements between two chronic autonomic disorders: multiple system atrophy and pure autonomic failure. ( 18805037 )
2009
18
Hyposmia in pure autonomic failure. ( 19433741 )
2009
19
Reduced perfusion in the anterior cingulate cortex of patients with pure autonomic failure: an 123I-IMP SPECT study. ( 19684240 )
2009
20
Renal impairment of pure autonomic failure. ( 19738158 )
2009
21
Exercise-induced hypertension in pure autonomic failure. ( 19538201 )
2009
22
Effects of water drinking on cardiovascular responses to supine exercise and on orthostatic hypotension after exercise in pure autonomic failure. ( 18469030 )
2008
23
Central dopamine deficiency in pure autonomic failure. ( 18363034 )
2008
24
Frequent nocturnal vocalization in pure autonomic failure. ( 18534130 )
2008
25
Pure autonomic failure followed by amyotrophy. ( 17339594 )
2007
26
Stress induced hypotension in pure autonomic failure. ( 16354738 )
2006
27
Hemodynamic effects of clonidine in two contrasting models of autonomic failure: multiple system atrophy and pure autonomic failure. ( 16404729 )
2006
28
Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. ( 16818943 )
2006
29
Cevimeline hydrochloride improved cholinergic dysfunction in a patient with pure autonomic failure. ( 15995794 )
2006
30
Chronic intestinal pseudo-obstruction as the initial feature of pure autonomic failure. ( 16705209 )
2006
31
Cerebral vasomotor reactivity in Parkinson's disease, multiple system atrophy and pure autonomic failure. ( 16438986 )
2006
32
REM sleep behavioral disorder in pure autonomic failure (PAF). ( 16505328 )
2006
33
Pure autonomic failure with altered dopamine transporter imaging. ( 16606777 )
2006
34
Cognitive functioning in orthostatic hypotension due to pure autonomic failure. ( 16683070 )
2006
35
Skin vasomotor reflex responses in two contrasting groups of autonomic failure: multiple system atrophy and pure autonomic failure. ( 16845569 )
2006
36
Differences in overshoot of blood pressure after head-up tilt in two groups with chronic autonomic failure: pure autonomic failure and multiple system atrophy. ( 15654557 )
2005
37
Progression and prognosis in pure autonomic failure (PAF): comparison with multiple system atrophy. ( 15965200 )
2005
38
Rate of change in cerebral oxygenation and blood pressure in response to passive changes in posture: a comparison between pure autonomic failure patients and controls. ( 16594152 )
2005
39
Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure. ( 16269589 )
2005
40
Pressor effect of water instilled via a gastrostomy tube in pure autonomic failure. ( 15296798 )
2004
41
Pure autonomic failure: an immaculate misconception? ( 15452282 )
2004
42
An explanation of the unexpected efficacy of L-DOPS in pure autonomic failure. ( 15666060 )
2004
43
Social and motivational functioning is not critically dependent on feedback of autonomic responses: neuropsychological evidence from patients with pure autonomic failure. ( 15381028 )
2004
44
The effects of water ingestion on orthostatic hypotension in two groups of chronic autonomic failure: multiple system atrophy and pure autonomic failure. ( 15548493 )
2004
45
Effect of posture on blood and intraocular pressures in multiple system atrophy, pure autonomic failure, and baroreflex failure. ( 14597588 )
2003
46
Variations in the dopamine beta-hydroxylase gene are not associated with the autonomic disorders, pure autonomic failure, or multiple system atrophy. ( 12833405 )
2003
47
Haemodynamic responses during head-up tilt and tilt reversal in two groups with chronic autonomic failure: pure autonomic failure and multiple system atrophy. ( 12021943 )
2002
48
Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. ( 12438492 )
2002
49
The cardiovascular effects of metoclopramide in multiple system atrophy and pure autonomic failure. ( 11605821 )
2001
50
L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. ( 11710796 )
2001

Variations for Pure Autonomic Failure

Expression for Pure Autonomic Failure

Search GEO for disease gene expression data for Pure Autonomic Failure.

Pathways for Pure Autonomic Failure

Pathways related to Pure Autonomic Failure according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 DDC GNB3 MAOA MAOB NPPA SNCA
2
Show member pathways
12.51 ACHE DDC GNB3 MAOA MAOB TH
3 12.4 DBH DDC GNB3 SNCA TH
4
Show member pathways
12.11 ACE ACHE GNB3 REN
5 12.05 DDC GNB3 MAOA TH
6
Show member pathways
11.83 DDC MAOA MAOB TH
7 11.79 DDC GNB3 MAOA MAOB
8 11.66 DDC SNCA TH
9 11.66 DBH DDC MAOA TH
10
Show member pathways
11.43 DBH DDC MAOA MAOB TH
11
Show member pathways
11.3 DBH DDC TH
12
Show member pathways
11.23 DDC MAOA MAOB
13
Show member pathways
11.19 ACHE DBH MAOA TH
14 11.16 MAOB SNCA TH
15
Show member pathways
11.02 ACHE MAOA
16
Show member pathways
10.72 MAOA MAOB
17
Show member pathways
10.68 MAOA MAOB
18 10.58 ACHE DDC TH
19 10.4 DDC MAOA MAOB TH
20
Show member pathways
10.36 ACHE DBH DDC MAOA TH

GO Terms for Pure Autonomic Failure

Cellular components related to Pure Autonomic Failure according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 ACE ACHE DBH EPO NPPA REN
2 synaptic vesicle GO:0008021 9.33 DDC SNCA TH
3 extracellular space GO:0005615 9.23 ACE ACHE DBH EPO NPPA REN

Biological processes related to Pure Autonomic Failure according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.88 MAOB REN SNCA TH
2 response to lipopolysaccharide GO:0032496 9.77 EPO MAOB REN SNCA TH
3 cellular response to drug GO:0035690 9.69 DDC REN TH
4 response to amphetamine GO:0001975 9.63 DBH TH
5 response to immobilization stress GO:0035902 9.62 REN TH
6 regulation of blood pressure GO:0008217 9.62 ACE GNB3 NPPA REN
7 positive regulation of endocytosis GO:0045807 9.61 NEDD4L SNCA
8 response to metal ion GO:0010038 9.61 NEDD4L TH
9 synaptic transmission, dopaminergic GO:0001963 9.6 SNCA TH
10 response to corticosterone GO:0051412 9.59 MAOB TH
11 multicellular organism aging GO:0010259 9.58 DDC TH
12 beta-amyloid metabolic process GO:0050435 9.57 ACE REN
13 neurotransmitter biosynthetic process GO:0042136 9.56 ACHE TH
14 angiotensin maturation GO:0002003 9.55 ACE REN
15 cellular response to alkaloid GO:0071312 9.54 DDC TH
16 response to salt stress GO:0009651 9.52 EPO TH
17 norepinephrine biosynthetic process GO:0042421 9.49 DBH TH
18 response to pyrethroid GO:0046684 9.48 DDC TH
19 aminergic neurotransmitter loading into synaptic vesicle GO:0015842 9.46 DDC TH
20 isoquinoline alkaloid metabolic process GO:0033076 9.43 DDC TH
21 neurotransmitter catabolic process GO:0042135 9.43 ACHE MAOA MAOB
22 phytoalexin metabolic process GO:0052314 9.4 DDC TH
23 dopamine biosynthetic process GO:0042416 9.33 DDC SNCA TH
24 dopamine catabolic process GO:0042420 9.13 DBH MAOA MAOB
25 catecholamine biosynthetic process GO:0042423 8.8 DBH DDC TH
26 oxidation-reduction process GO:0055114 10.02 DBH MAOA MAOB SNCA TH

Molecular functions related to Pure Autonomic Failure according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.35 DBH MAOA MAOB SNCA TH
2 hormone activity GO:0005179 9.33 EPO NPPA TTR
3 amino acid binding GO:0016597 9.32 DDC TH
4 ferrous iron binding GO:0008198 9.26 SNCA TH
5 primary amine oxidase activity GO:0008131 8.62 MAOA MAOB

Sources for Pure Autonomic Failure

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....